
Wegovy for Teens: Who Can Use It From Age 12
Wegovy injections are approved for teens 12+ with obesity. STEP TEENS results, label dosing, teen side effects, the pill and the 2026 mood label change.
Written by Diana Gangan. Updated November 15, 2026.
Yes, Wegovy injections are FDA-approved for teenagers aged 12 and older who have obesity, used together with a reduced-calorie diet and more physical activity. For children and teens, obesity is defined by comparing body mass index (BMI) with other young people of the same age and sex: a BMI at or above the 95th percentile, meaning higher than 95 out of 100 peers, was the entry point in the pediatric trial. In that trial, called STEP TEENS, teens on Wegovy reduced their BMI by 16.1% over 68 weeks, while BMI rose by 0.6% with placebo. Teens use the same step-by-step dose schedule as adults, but the higher 7.2 mg dose and the Wegovy pill are for adults only as of November 2026. A pediatric clinician prescribes and monitors treatment. This guide covers who qualifies, trial results, label dosing, side effects that are more common in teens, the American Academy of Pediatrics guideline and the January 2026 label change on mood.
Wegovy for Teens: The Short Answer
- 1Wegovy injections are approved for ages 12 and older with obesity; approval was announced in December 2022.
- 2In STEP TEENS, BMI fell 16.1% with Wegovy versus a 0.6% rise with placebo over 68 weeks.
- 3Teens follow the same label escalation as adults, up to a 2.4 mg (recommended) or 1.7 mg weekly maintenance dose.
- 4The 7.2 mg dose and Wegovy tablets have not been established in people under 18.
- 5Stomach side effects were common, and gallbladder problems, low blood pressure and rash were more frequent in teens than in adults.
- 6In January 2026 the FDA asked for the suicidal behavior and ideation warning to be removed from the Wegovy label.
Is Wegovy Approved for Teenagers?
Yes. The current Wegovy label, revised in June 2026, lists the injection for weight reduction in adults and in "pediatric patients aged 12 years and older with obesity". Novo Nordisk announced the FDA approval for this age group on December 23, 2022. Wegovy was not the first weight-loss drug approved for teens: Saxenda (liraglutide) had been approved for adolescents in December 2020. Wegovy contains semaglutide, a drug that copies a gut hormone called GLP-1, which reduces appetite and slows how fast the stomach empties. More on how it works is in how much weight you can lose on Wegovy.
Which Teens Qualify for Wegovy?
The label indication is age 12 or older with obesity. Adults are usually classified with a single BMI cutoff, but children and teens are still growing, so their BMI is compared with growth charts for their age and sex. The pediatric trial enrolled teens with a BMI at or above the 95th percentile for age and sex. A pediatrician or other clinician measures height and weight, plots the BMI percentile and decides whether medicine is appropriate, alongside changes to eating, activity and sleep. Wegovy is not meant for teens who simply want to lose a few pounds.
Insurance coverage for teens varies by plan, and prior authorization is common; see does insurance cover Wegovy.
What Did the STEP TEENS Trial Show?
STEP TEENS, published in the New England Journal of Medicine in December 2022, randomized 201 teens with obesity to weekly Wegovy or placebo for 68 weeks, in a 2-to-1 ratio. In total, 180 participants (90%) completed treatment. BMI fell by an average of 16.1% with Wegovy and rose by 0.6% with placebo, a difference of 16.7 percentage points. Some summaries of the trial give the placebo result as a decrease, but the published paper and the label both report an increase.
Measured another way, 73% of teens on Wegovy lost at least 5% of their body weight, compared with 18% on placebo, according to the NEJM paper. The label reports that 77.1% versus 19.7% reduced their BMI by at least 5%. About 10% of teens stopped treatment early in both groups.
STEP TEENS results: Wegovy vs placebo over 68 weeks
Number randomized (label analysis)
134
67
Average BMI change
-16.1%
+0.6%
At least 5% BMI reduction (label)
77.1%
19.7%
At least 5% weight loss (NEJM)
73%
18%
Any stomach or bowel side effect
62%
42%
Gallstones (cholelithiasis)
3.8%
0%
Serious adverse events (NEJM)
11%
9%
Stopped treatment
10%
10%
How Is Wegovy Dosed for Teens?
Teens 12 and older follow the same label schedule as adults. The dose starts low and rises every 4 weeks so the body can adjust, which helps limit nausea. After the escalation, the maintenance dose is 2.4 mg once weekly (the recommended dose) or 1.7 mg once weekly. If a dose is not tolerated during escalation, the label says to consider delaying the next increase by 4 weeks. Your teen's clinician sets the exact plan; this table only shows what the label lists. More detail is in our Wegovy dosing schedule guide and Wegovy maintenance dose article.
Wegovy injection label dosing for ages 12 and older
Weeks 1 to 4
0.25 mg
Weeks 5 to 8
0.5 mg
Weeks 9 to 12
1 mg
Weeks 13 to 16
1.7 mg
Week 17 onward (maintenance)
2.4 mg (recommended) or 1.7 mg
7.2 mg
Adults only; not established in pediatric patients
The 7.2 mg dose appears in the label only under weight reduction in adults, and section 8.4 says its safety and effectiveness have not been established in pediatric patients; see Wegovy HD 7.2 mg. If a weekly injection is missed and the next dose is more than 2 days away, the label says to give it as soon as possible; otherwise, skip it and take the next dose on the usual day. A parent or caregiver should learn the injection technique too; see how to use the Wegovy pen.
What Side Effects Are More Common in Teens Than Adults?
Stomach and bowel side effects were the most common in the pediatric trial. According to the label, nausea occurred in 42% of teens on Wegovy versus 18% on placebo, vomiting in 36% versus 10%, diarrhea in 22% versus 19% and abdominal pain in 15% versus 6%.
The label also notes that some problems were more frequent in pediatric patients than in adults:
- 1Gallstones (cholelithiasis): 3.8% versus 0% on placebo
- 2Gallbladder inflammation (cholecystitis): 0.8% versus 0%
- 3Low blood pressure (hypotension): 2.3% versus 0%
- 4Rash: 3% versus 0%
- 5Hives (urticaria): 3% versus 0%
Severe or persistent belly pain, especially in the upper right side, can signal a gallbladder problem and needs prompt medical attention. Longer-term questions about GLP-1 drugs are covered in GLP-1 long-term side effects.
What Does the AAP Guideline Say About Weight-Loss Medication for Teens?
In January 2023 the American Academy of Pediatrics (AAP) released its first comprehensive clinical practice guideline on obesity in children and teens. It says pediatricians should offer weight-loss medication to adolescents 12 and older with obesity, according to each drug's approved uses, as an addition to health behavior and lifestyle treatment rather than a replacement for it. It also says teens 13 and older with severe obesity, defined as a BMI at or above 120% of the 95th percentile, should be evaluated for metabolic and bariatric surgery. Sandra Hassink, MD, said there is "no evidence that 'watchful waiting'" is appropriate for children with obesity.
Can Teens Take the Wegovy Pill?
No, not according to the current label. Wegovy tablets were approved on December 22, 2025, for adults, at 25 mg once daily; in the OASIS 4 trial adults lost 16.6% of body weight on average. The label states that safety and effectiveness of Wegovy tablets "have not been established in pediatric patients", and we found no pediatric trials of the tablets. For teens, the weekly injection is the approved form. The two forms are compared for adults in Wegovy pill vs injection.
Does Wegovy Affect Mood? What Changed on the Label in 2026
Earlier Wegovy labels carried a warning about suicidal behavior and ideation (thoughts of suicide). On January 13, 2026, the FDA issued a Drug Safety Communication asking for that warning to be removed from the labels of Saxenda, Wegovy and Zepbound. The FDA based this on a meta-analysis of 91 trials with 107,910 patients and a study in its Sentinel safety system, which together found no increased risk. The June 2026 Wegovy label lists the warning as removed.
The FDA still advises patients to tell their clinician about any new or worsening depression. Teens with obesity can face stigma, low mood and eating concerns, so mental health should stay part of regular check-ups whether or not a teen takes medicine. If a teen has thoughts of suicide, call or text 988, the Suicide and Crisis Lifeline in the United States.
What Happens When a Teen Stops Wegovy?
We did not review long-term data on what happens after teens stop Wegovy, so we cannot give figures here. What is known for adults is discussed in what happens when you stop taking Wegovy. Obesity is generally treated as a long-term condition, so ask your teen's clinician how long treatment is expected to last and what the plan is if it stops.
When to Talk to Your Doctor
- 1Before starting, to confirm the BMI percentile and discuss lifestyle treatment
- 2If vomiting or diarrhea makes it hard to eat or drink, which can lead to dehydration
- 3If there is severe belly pain, especially in the upper right or spreading to the back
- 4If your teen feels dizzy or faint, which can signal low blood pressure
- 5If a rash, hives or swelling appears
- 6If your teen shows new or worsening low mood; in a crisis, call or text 988
Questions to Ask Your Teen's Doctor
- 1Does my teen's BMI percentile meet the label's definition of obesity?
- 2What lifestyle support will go alongside the medicine?
- 3How often will you check weight, growth, blood pressure and mood?
- 4What should we do if side effects make a dose increase hard?
- 5Which maintenance dose do you plan, and why?
- 6How long do you expect treatment to last, and what happens if we stop?
- 7Is my teen a candidate for other options, such as bariatric surgery evaluation?
The Bottom Line
Wegovy injections are approved for teens 12 and older with obesity, and in STEP TEENS they reduced BMI by about 16% compared with placebo. Teens use the same label dose schedule as adults up to 2.4 mg weekly, but the 7.2 mg dose and the Wegovy pill are not established for under-18s. Stomach side effects are common, and gallbladder problems, low blood pressure and rash were seen more often than in adults. The suicidal ideation warning was removed in 2026, but mood should still be watched. A pediatric clinician should prescribe and monitor treatment.
FAQ
Yes, if they have obesity. The label approves Wegovy injections for pediatric patients aged 12 and older with obesity, alongside diet and activity changes, under a clinician's care.
Teens follow the adult label schedule: 0.25 mg weekly for 4 weeks, then 0.5 mg, 1 mg and 1.7 mg for 4 weeks each, with maintenance at 2.4 mg (recommended) or 1.7 mg. The 7.2 mg dose is for adults only.
STEP TEENS followed teens for 68 weeks, and serious adverse events were 11% versus 9% with placebo. Longer-term data in teens are limited, so regular follow-up with a clinician is important.
No. The label says safety and effectiveness of Wegovy tablets have not been established in pediatric patients. Teens use the weekly injection.
In January 2026 the FDA asked for the suicidal behavior and ideation warning to be removed after large analyses found no increased risk. The FDA still advises reporting new or worsening depression to a clinician.
The pediatric trial enrolled teens with a BMI at or above the 95th percentile for age and sex, which is the definition of obesity in children and teens. A clinician plots this on a growth chart.
Sources
- 1Novo Nordisk. WEGOVY (semaglutide) injection and tablets prescribing information, revised 06/2026, U.S. Food and Drug Administration, 2026
- 2Novo Nordisk. WEGOVY (semaglutide) injection and tablets prescribing information, January 2026, U.S. Food and Drug Administration, 2026
- 3Weghuber D et al. Once-weekly semaglutide in adolescents with obesity, New England Journal of Medicine, 2022
- 4FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications, U.S. Food and Drug Administration, 2026
- 5American Academy of Pediatrics issues its first comprehensive guideline on evaluating, treating children and adolescents with obesity, American Academy of Pediatrics, 2023
- 6Krewson C. FDA approves semaglutide for obesity in adolescents, Contemporary Pediatrics, 2023
- 7Chen E. Wegovy may help teens with obesity lose weight but isn't a magic bullet, STAT, 2022
- 8Saraceno N. FDA Approves Novo Nordisk's Wegovy Pill, Marking First Oral GLP-1 for Weight Management, Pharmaceutical Commerce, 2025
This article is general information, not medical advice. Weight-loss medicine for teens should be prescribed and monitored by a pediatric clinician. Wegovy is made by Novo Nordisk.

Diana Gangan
Author
Comments (0)
Be the first to comment on this article.




